These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 23987572

  • 21. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV, Siepmann T, Engel J, Schubert-Fritschle G, Eckel R, Mirlach L, Kirchner T, Jung A, Gesierich A, Ruzicka T, Flaig MJ, Berking C.
    BMC Cancer; 2017 Aug 10; 17(1):536. PubMed ID: 28797232
    [Abstract] [Full Text] [Related]

  • 22. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J, Wu Y, Li C, Wang R, Song H, Ren G, Guo W.
    J Oral Pathol Med; 2016 Apr 10; 45(4):295-301. PubMed ID: 26399561
    [Abstract] [Full Text] [Related]

  • 23. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
    Tschandl P, Berghoff AS, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H.
    PLoS One; 2013 Apr 10; 8(7):e69639. PubMed ID: 23861977
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA, Montesion M, Shah N, Sharaf R, Pavlick DC, Sokol ES, Alexander B, Venstrom J, Elvin JA, Ross JS, Williams KJ, Tse JY, Mochel MC.
    Mod Pathol; 2020 Dec 10; 33(12):2397-2406. PubMed ID: 32483240
    [Abstract] [Full Text] [Related]

  • 32. [ Spectrum of oncogene mutations is different in melanoma subtypes].
    Mazurenko NN, Tsyganova IV, Lushnikova AA, Ponkratova DA, Anurova OA, Cheremushkin EA, Mikhailova IN, Demidov LV.
    Mol Biol (Mosk); 2015 Dec 10; 49(6):1022-9. PubMed ID: 26710785
    [Abstract] [Full Text] [Related]

  • 33. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S, Leone DA, Biswas A, Deng A, Jukic D, Singh R, Sundram U, Mahalingam M.
    Hum Pathol; 2018 Dec 10; 82():206-214. PubMed ID: 30120967
    [Abstract] [Full Text] [Related]

  • 34. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC, Küsters-Vandevelde HV, De Hullu J, van Duijn LM, Rijntjes J, Bovée JV, Groenen PJ, Blokx WA.
    Gynecol Oncol; 2014 Jul 10; 134(1):10-4. PubMed ID: 24802725
    [Abstract] [Full Text] [Related]

  • 35. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.
    Melanoma Res; 2012 Jun 10; 22(3):202-14. PubMed ID: 22456166
    [Abstract] [Full Text] [Related]

  • 36. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M, Mogha A, Lespagnol A, Fautrel A, Mouchet N, Le Gall F, Paumier V, Lefeuvre-Plesse C, Rioux-Leclerc N, Mosser J, Oger E, Adamski H, Galibert MD, Lesimple T.
    J Eur Acad Dermatol Venereol; 2015 Aug 10; 29(8):1530-8. PubMed ID: 25623140
    [Abstract] [Full Text] [Related]

  • 37. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS, Haydu LE, Kakavand H, Menzies AM, Hamilton AL, Yu B, Ng CC, Cooper WA, Thompson JF, Kefford RF, O'Toole SA, Scolyer RA, Long GV.
    Br J Cancer; 2014 Jul 15; 111(2):292-9. PubMed ID: 24918823
    [Abstract] [Full Text] [Related]

  • 38. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.
    Histopathology; 2016 Oct 15; 69(4):680-6. PubMed ID: 27151331
    [Abstract] [Full Text] [Related]

  • 39. Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.
    Jahn SW, Kashofer K, Halbwedl I, Winter G, El-Shabrawi-Caelen L, Mentzel T, Hoefler G, Liegl-Atzwanger B.
    Mod Pathol; 2015 Jul 15; 28(7):895-903. PubMed ID: 25769001
    [Abstract] [Full Text] [Related]

  • 40. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW, Choe JY, Kwon MJ, Lee HK, Kang HS, Nam ES, Cho SJ, Park HR, Min SK, Seo J, Kim YJ, Kim NY, Kim HY.
    Pathol Res Pract; 2019 Dec 15; 215(12):152671. PubMed ID: 31630873
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.